Market cap
$8,570 Mln
Revenue (TTM)
$800 Mln
P/E Ratio
20.4
P/B Ratio
14.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 17.28 | 70.27 | 76.08 | 221.54 | 219.17 |
| EBIT | -- | -- | 15.19 | 38.94 | 18.45 |
| Net Profit | -60.66 | -72.40 | 630.24 | 65.26 | 26.83 |
| EPS | -59.96 | -71.47 | 633.67 | 60.91 | 24.64 |
| Book Value | -- | -- | 193.03 | 111.91 | -0.57 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 15.94 | -2,548.47 | 14.04 | 21.76 | 15.08 |
| Net Margin
| -- | -3,869.51 | 55.22 | -- | -- |
| Return on equity
| 42.18 | -23.37 | 70.52 | 102.75 | 12.21 |
| Return on Capital
| 25.66 | -20.03 | -- | 64.58 | 6.26 |
| Return on Assets
| 21.50 | -16.57 | 31.73 | 54.50 | 5.15 |
| Debt to Equity (x)
| -- | -- | 1.23 | 0.40 | 1.14 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
64.58
|
6.26
|
6.14
|
-97.77
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
70.52
Higher than Peers by 110.85
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
70.52
|
102.75
|
12.21
|
11.57
|
-151.36
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
31.73
Higher than Peers by 62.98
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
31.73
|
54.50
|
5.15
|
4.84
|
-78.09
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
14.04
Higher than Peers by 96.64
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
14.04
|
21.76
|
15.08
|
10.99
|
-7,670.41
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
55.22
Higher than Peers by 146.52
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
55.22
|
72.56
|
7.11
|
5.42
|
-8,036.34
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
76.08
Higher than Peers by 22.05
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
76.08
|
0.87
|
0.41
|
82.90
|
-0.58
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
15.19
Higher than Peers by 16.21
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
15.19
|
170.28
|
93.25
|
112.02
|
37.62
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
630.24
Higher than Peers by 637.78
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
630.24
|
1,812.41
|
84.52
|
105.66
|
35.70
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
633.67
Higher than Peers by 619.44
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
633.67
|
18.23
|
0.65
|
1.05
|
0.38
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
125.86
Higher than Peers by 135.99
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
125.86
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.23
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
1.23
|
0.40
|
1.14
|
0.69
|
1.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
0.00
|
0.00
|
0.01
|
0.01
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.27
Lower than Peers by 1.54
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
4.27
|
4.10
|
6.25
|
5.92
|
3.16
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
3.72
Lower than Peers by 1.98
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
3.72
|
3.29
|
5.03
|
5.18
|
3.16
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
3.71
Higher than Peers by 5.80
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
3.71
|
5.02
|
2.07
|
2.04
|
-20.96
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
50.22
Higher than Peers by 31.21
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
50.22
|
49.59
|
39.27
|
21.87
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.57
Higher than Peers by 0.51
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
0.57
|
0.75
|
0.73
|
0.89
|
0.01
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
128.85
|
100.07
|
39.93
|
91.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
428.02
|
713.12
|
514.66
|
-16,266.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
300.65
|
459.18
|
1,040.23
|
64,306.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
256.22
|
354.01
|
-485.64
|
-80,482.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
20.43
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
20.43
|
10.62
|
206.28
|
192.87
|
-7.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
14.42
Higher than Peers by 9.09
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
14.42
|
7.33
|
21.69
|
15.23
|
27.69
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
63.93
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
63.93
|
36.24
|
95.51
|
89.55
|
-7.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
8,570
Higher than Peers by 8,429
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
8,570
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|